Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea.
Department of Medical Biotechnology, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea.
In Vivo. 2021 Jul-Aug;35(4):2151-2157. doi: 10.21873/invivo.12485.
BACKGROUND/AIM: Osteosarcoma is the most common type of bone cancer, but current therapeutic interventions remain largely insufficient. The development of new treatment strategies is needed, and moreover, optimal rodent models are necessary for testing the efficacy of new treatment modalities of osteosarcoma. Humanized mice carry human hematopoietic and immune systems, and are considered an ideal tool to study human diseases including cancer immunology. Herein, we performed a preliminary study toward developing an in vivo bioluminescent osteosarcoma model using humanized immunodeficient (NSG) mice.
To establish the xenograft and orthotopic mouse model, NSG mice engrafted with human CD34 hematopoietic stem cells were injected with luciferase-expressing KHOS/NP cells at two different time points. Bioluminescence images were obtained to monitor in vivo tumor growth and metastasis. Influence of the degree of human cell engraftment on tumor growth and metastatic behavior was analyzed and compared between the two groups.
KHOS/NP-luc cells injected in humanized NSG mice formed macroscopic tumors. The percentage of human CD45+ cells in these models was similar, but the percentage of human CD45+CD3+ and their subset was higher in the late-injection group compared to that of the early-injection group. The rate of KHOS/NP tumor growth was higher in the early-injection group than in the late-injection group. In the present study, human hematopoietic cell engraftment was not influenced by KHOS/NP cell injection, but KHOS/NP osteosarcoma showed more aggressive behavior in the early-injection group than that in the late-injection group, forming larger tumor volumes and earlier metastases.
The results indicated that tumor growth and progression in humanized NSG mice may have been influenced by higher levels of human cell engraftment, especially T cells. Although there exist some limitations to our study, our preliminary results can provide the basis for the development of a humanized osteosarcoma mouse model.
背景/目的:骨肉瘤是最常见的骨癌类型,但目前的治疗干预措施仍然远远不够。需要开发新的治疗策略,此外,还需要最佳的啮齿动物模型来测试骨肉瘤新治疗方式的疗效。人源化小鼠携带人类造血和免疫系统,被认为是研究包括癌症免疫学在内的人类疾病的理想工具。在此,我们使用人源化免疫缺陷(NSG)小鼠初步研究了建立体内发光骨肉瘤模型的方法。
为了建立异种移植和原位小鼠模型,将人 CD34 造血干细胞植入的 NSG 小鼠分别在两个不同时间点注射表达荧光素酶的 KHOS/NP 细胞。通过生物发光成像监测体内肿瘤生长和转移情况。分析并比较了两组之间人细胞植入程度对肿瘤生长和转移行为的影响。
在人源化 NSG 小鼠中注射 KHOS/NP-luc 细胞形成了肉眼可见的肿瘤。这两种模型中人类 CD45+细胞的比例相似,但晚期注射组中人类 CD45+CD3+细胞及其亚群的比例高于早期注射组。早期注射组 KHOS/NP 肿瘤的生长速度高于晚期注射组。在本研究中,KHOS/NP 细胞的注射并未影响人造血细胞的植入,但 KHOS/NP 骨肉瘤在早期注射组的表现比晚期注射组更为侵袭性,形成更大的肿瘤体积并更早发生转移。
结果表明,人源化 NSG 小鼠中的肿瘤生长和进展可能受到更高水平的人细胞植入的影响,尤其是 T 细胞。尽管我们的研究存在一些局限性,但初步结果可为开发人源化骨肉瘤小鼠模型提供基础。